Skip to main content
Theraclion SA logo

Theraclion SA — Investor Relations & Filings

Ticker · ALTHE ISIN · FR0010120402 LEI · 9695007X7HA7A1GCYD29 PA Manufacturing
Open in API
Filings indexed 399 across all filing types
Latest filing 2015-06-03 Legal Proceedings Report
Country FR France
Listing PA ALTHE

About Theraclion SA

https://www.theraclion.com/?_ga=2.14878…

Theraclion SA is a medical device company specializing in the development and marketing of non-invasive therapeutic solutions using High-Intensity Focused Ultrasound (HIFU). The company's technology, known as echotherapy, provides a non-surgical alternative for tissue ablation. Its flagship product, SONOVEIN®, is a robotic solution for the non-invasive treatment of varicose veins. The system uses external ultrasound beams to ablate the target vein without incisions, catheters, or sedation, allowing for immediate patient recovery. Theraclion also developed ECHOPULSE®, a system for the treatment of thyroid nodules and breast fibroadenomas. The company's core focus is on providing precise, non-invasive treatments that reduce risks and recovery time compared to traditional surgical procedures.

Recent filings

Filing Released Lang Actions
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Legal Proceedings Report Classification · 99% confidence The document is a press release dated June 3, 2015, from Theraclion announcing that it has received agreement from the FDA to review the clinical trial submission plan for its Echopulse® system for the US market. It discusses regulatory pathways, planned clinical studies (pivot and feasibility), and market potential. This type of announcement, detailing progress in regulatory or clinical strategy, does not fit neatly into the specific financial reporting categories (10-K, IR, ER, etc.). It is a general corporate update concerning regulatory/legal progress. Since it is not a formal legal proceeding report (LTR) but rather a strategic update on regulatory engagement, and it is not a standard financial release, it best fits the general 'Regulatory Filings' fallback category (RNS) as a significant corporate announcement that doesn't match other specific codes. Given the content focuses heavily on FDA interaction and clinical trial planning, it is a material corporate event announcement.
2015-06-03 French
Communicated under the obligation to provide permanent information / Other communications
Regulatory Filings Classification · 95% confidence The document is a press release dated June 3, 2015, announcing that Theraclion has filed a Pre-Submission with the FDA regarding the regulatory pathway for its Echopulse System. It discusses clinical trials, regulatory milestones, and market potential. This type of announcement, detailing progress in regulatory submissions, legal/regulatory matters, or clinical trials, fits best under the 'Legal Proceedings Report' (LTR) category if it relates to regulatory hurdles or the 'Regulatory Filings' (RNS) as a general announcement. Since it specifically details interactions and submissions to a regulatory body (FDA) concerning product approval, and it is not a formal financial report (like 10-K, IR, ER), nor a management change (MANG), nor a director dealing (DIRS), it is best classified as a general regulatory update. Given the options, 'LTR' covers significant legal/regulatory actions, and 'RNS' is the general regulatory fallback. Because this is a proactive announcement about a regulatory submission process rather than a response to an adverse action or a formal financial filing, 'RNS' (Regulatory Filings/General Regulatory Announcements) is the most appropriate general classification for this type of corporate news release that doesn't fit a more specific financial or governance category.
2015-06-03 English
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
AGM Information Classification · 99% confidence The document is titled "Assemblée générale ordinaire et extraordinaire annuelle de Theraclion" (Annual Ordinary and Extraordinary General Meeting of Theraclion) and explicitly details the resolutions adopted by shareholders, including the approval of 2014 accounts and the appointment/re-appointment of directors. This content is directly related to the proceedings and outcomes of an Annual General Meeting (AGM). Therefore, the appropriate classification is AGM Information (AGM-R).
2015-04-29 French
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Regulatory Filings Classification · 95% confidence The document is a press release dated April 27, 2015, from THERACLION announcing an expansion of insurance coverage in Germany for their Echotherapy treatment. It details business developments, partnerships with insurance companies, and quotes the CEO. This type of announcement, focusing on business progress, market access, and operational updates rather than formal financial results (like 10-K or ER) or specific regulatory filings, best fits the category for general corporate news or updates that might be released via regulatory channels but are not the core financial reports themselves. Since it is a news announcement about business progress and market access, it is most closely aligned with a general regulatory announcement or news release. Given the options, 'Regulatory Filings' (RNS) serves as the best general category for corporate news releases that don't fit the highly specific financial or governance codes. It is not an Earnings Release (ER), Interim Report (IR), or a specific legal/governance document. It is a general corporate update.
2015-04-27 French
Communicated under the obligation to provide permanent information / Other communications
Regulatory Filings Classification · 95% confidence The document is a press release dated April 27, 2015, announcing an operational update regarding insurance coverage expansion in Germany for the company's Echotherapy treatment. It details business progress, contract signings, and quotes the CEO. This type of announcement, which is not a formal regulatory filing (like 10-K or IR) but rather a general business update intended for investors and the public, fits best under the 'Regulatory Filings' (RNS) category as a general announcement, or potentially an 'Earnings Release' (ER) if it were tied to a specific reporting period's results, but here it is purely operational news. Given the options, RNS serves as the best general regulatory/business announcement fallback when specific categories like ER, CAP, or DIV do not apply. It is not a transcript (CT), a formal report (10-K, IR), or a management discussion (MDA). Since it is a general announcement of business progress, RNS is the most appropriate classification.
2015-04-27 English
Communicated under the obligation to provide permanent information / Other communications
Board/Management Information Classification · 99% confidence The document is a press release dated April 15, 2015, announcing the hiring of a new Business Development Director for Asia. This type of announcement, detailing changes in senior management or key personnel appointments, directly corresponds to the definition of 'Board/Management Information'. The document is not a formal regulatory filing like a 10-K, an earnings release, or a dividend notice. Therefore, the appropriate code is MANG.
2015-04-15 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.